Loading…

Effects and side effects of migraine prophylaxis in children

Background Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent an...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics international 2022-01, Vol.64 (1), p.e15094-n/a
Main Authors: Tekin, Hande, Edem, Pınar
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03
cites cdi_FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03
container_end_page n/a
container_issue 1
container_start_page e15094
container_title Pediatrics international
container_volume 64
creator Tekin, Hande
Edem, Pınar
description Background Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients. Methods One hundred eighty‐six patients aged 6–18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH‐3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre‐ and post‐treatment values were compared. Results The median age of the patients was 14 years (range, 6–18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations. Conclusions Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.
doi_str_mv 10.1111/ped.15094
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2610077616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890389380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYXvoAMuNHFtMnkMgm4kVovUNCFgruQSTI2ZS416aB9e1On3QiezTkcPj5-fgDOERyjOJOVNWNEoSAHYIgIydIMwvfDeOOMpxyyfABOQlhCCHnOyTEYYCIgzXIxBDezsrR6HRLVmCQ4YxO7e7RlUrsPr1xjk5VvV4tNpb5dSFyT6IWrjLfNKTgqVRXs2W6PwNv97HX6mM6fH56mt_NUYwJJirTggrGCZBRZWhYFU4pwzjTGpNDWQqMNLRSK0ZEgpRE0J8gSSnFucmQgHoGr3htzfHY2rGXtgrZVpRrbdkFmDEGY5wyxiF7-QZdt55uYTmZcQMwF5lvhdU9p34bgbSlX3tXKbySCclupjJXK30oje7EzdkUdv3ty32EEJj3w5Sq7-d8kX2Z3vfIHLMl93g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890389380</pqid></control><display><type>article</type><title>Effects and side effects of migraine prophylaxis in children</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tekin, Hande ; Edem, Pınar</creator><creatorcontrib>Tekin, Hande ; Edem, Pınar</creatorcontrib><description>Background Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients. Methods One hundred eighty‐six patients aged 6–18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH‐3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre‐ and post‐treatment values were compared. Results The median age of the patients was 14 years (range, 6–18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations. Conclusions Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.</description><identifier>ISSN: 1328-8067</identifier><identifier>EISSN: 1442-200X</identifier><identifier>DOI: 10.1111/ped.15094</identifier><identifier>PMID: 34905279</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Analgesics ; Child ; children ; Cyproheptadine ; Disease prevention ; Drug-Related Side Effects and Adverse Reactions - drug therapy ; Emergency medical care ; Fructose - adverse effects ; Headache ; Headaches ; Humans ; Infant ; Medical records ; Migraine ; Migraine Disorders - drug therapy ; Migraine Disorders - prevention &amp; control ; Patients ; Pediatrics ; Prophylaxis ; Propranolol ; Quality of Life ; Side effects ; side effects of drugs ; Topiramate ; Topiramate - adverse effects ; treatment</subject><ispartof>Pediatrics international, 2022-01, Vol.64 (1), p.e15094-n/a</ispartof><rights>2021 Japan Pediatric Society</rights><rights>2021 Japan Pediatric Society.</rights><rights>2022 Japan Pediatric Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03</citedby><cites>FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03</cites><orcidid>0000-0002-4407-164X ; 0000-0002-0395-7866</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34905279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tekin, Hande</creatorcontrib><creatorcontrib>Edem, Pınar</creatorcontrib><title>Effects and side effects of migraine prophylaxis in children</title><title>Pediatrics international</title><addtitle>Pediatr Int</addtitle><description>Background Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients. Methods One hundred eighty‐six patients aged 6–18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH‐3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre‐ and post‐treatment values were compared. Results The median age of the patients was 14 years (range, 6–18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations. Conclusions Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.</description><subject>Analgesics</subject><subject>Child</subject><subject>children</subject><subject>Cyproheptadine</subject><subject>Disease prevention</subject><subject>Drug-Related Side Effects and Adverse Reactions - drug therapy</subject><subject>Emergency medical care</subject><subject>Fructose - adverse effects</subject><subject>Headache</subject><subject>Headaches</subject><subject>Humans</subject><subject>Infant</subject><subject>Medical records</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Migraine Disorders - prevention &amp; control</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prophylaxis</subject><subject>Propranolol</subject><subject>Quality of Life</subject><subject>Side effects</subject><subject>side effects of drugs</subject><subject>Topiramate</subject><subject>Topiramate - adverse effects</subject><subject>treatment</subject><issn>1328-8067</issn><issn>1442-200X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKAzEUhoMotlYXvoAMuNHFtMnkMgm4kVovUNCFgruQSTI2ZS416aB9e1On3QiezTkcPj5-fgDOERyjOJOVNWNEoSAHYIgIydIMwvfDeOOMpxyyfABOQlhCCHnOyTEYYCIgzXIxBDezsrR6HRLVmCQ4YxO7e7RlUrsPr1xjk5VvV4tNpb5dSFyT6IWrjLfNKTgqVRXs2W6PwNv97HX6mM6fH56mt_NUYwJJirTggrGCZBRZWhYFU4pwzjTGpNDWQqMNLRSK0ZEgpRE0J8gSSnFucmQgHoGr3htzfHY2rGXtgrZVpRrbdkFmDEGY5wyxiF7-QZdt55uYTmZcQMwF5lvhdU9p34bgbSlX3tXKbySCclupjJXK30oje7EzdkUdv3ty32EEJj3w5Sq7-d8kX2Z3vfIHLMl93g</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Tekin, Hande</creator><creator>Edem, Pınar</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4407-164X</orcidid><orcidid>https://orcid.org/0000-0002-0395-7866</orcidid></search><sort><creationdate>202201</creationdate><title>Effects and side effects of migraine prophylaxis in children</title><author>Tekin, Hande ; Edem, Pınar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analgesics</topic><topic>Child</topic><topic>children</topic><topic>Cyproheptadine</topic><topic>Disease prevention</topic><topic>Drug-Related Side Effects and Adverse Reactions - drug therapy</topic><topic>Emergency medical care</topic><topic>Fructose - adverse effects</topic><topic>Headache</topic><topic>Headaches</topic><topic>Humans</topic><topic>Infant</topic><topic>Medical records</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Migraine Disorders - prevention &amp; control</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prophylaxis</topic><topic>Propranolol</topic><topic>Quality of Life</topic><topic>Side effects</topic><topic>side effects of drugs</topic><topic>Topiramate</topic><topic>Topiramate - adverse effects</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tekin, Hande</creatorcontrib><creatorcontrib>Edem, Pınar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tekin, Hande</au><au>Edem, Pınar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects and side effects of migraine prophylaxis in children</atitle><jtitle>Pediatrics international</jtitle><addtitle>Pediatr Int</addtitle><date>2022-01</date><risdate>2022</risdate><volume>64</volume><issue>1</issue><spage>e15094</spage><epage>n/a</epage><pages>e15094-n/a</pages><issn>1328-8067</issn><eissn>1442-200X</eissn><abstract>Background Migraine is the primary cause of headache in children. Most patients can be treated with lifestyle changes and acute attack prophylaxis. Prophylaxis should be considered when symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. We aimed to compare the efficacy and side effects of drugs used in migraine prophylaxis, chosen according to the clinical and/or demographic characteristics of the patients. Methods One hundred eighty‐six patients aged 6–18 years were evaluated and who were diagnosed with migraine according to The International Classification of Headache Disorders, 3rd edition beta version (ICH‐3β). Propranolol, topiramate, flunarizine, and cyproheptadine were given as prophylactic treatment. The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre‐ and post‐treatment values were compared. Results The median age of the patients was 14 years (range, 6–18 years) and the mean duration of headache was 29.6 ± 21.02 months. The mean PedMIDAS score was 29.9 ± 21.2 before and 14.9 ± 12.5 after treatment. Most reduction in the frequency of attacks was observed in the topiramate group. All four drugs significantly reduced the PedMIDAS score. The most common side effect was palpitations. Conclusions Significant improvement was found in PedMIDAS scores in all drug groups. Topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>34905279</pmid><doi>10.1111/ped.15094</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4407-164X</orcidid><orcidid>https://orcid.org/0000-0002-0395-7866</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1328-8067
ispartof Pediatrics international, 2022-01, Vol.64 (1), p.e15094-n/a
issn 1328-8067
1442-200X
language eng
recordid cdi_proquest_miscellaneous_2610077616
source Wiley-Blackwell Read & Publish Collection
subjects Analgesics
Child
children
Cyproheptadine
Disease prevention
Drug-Related Side Effects and Adverse Reactions - drug therapy
Emergency medical care
Fructose - adverse effects
Headache
Headaches
Humans
Infant
Medical records
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
Patients
Pediatrics
Prophylaxis
Propranolol
Quality of Life
Side effects
side effects of drugs
Topiramate
Topiramate - adverse effects
treatment
title Effects and side effects of migraine prophylaxis in children
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A41%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20and%20side%20effects%20of%20migraine%20prophylaxis%20in%20children&rft.jtitle=Pediatrics%20international&rft.au=Tekin,%20Hande&rft.date=2022-01&rft.volume=64&rft.issue=1&rft.spage=e15094&rft.epage=n/a&rft.pages=e15094-n/a&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1111/ped.15094&rft_dat=%3Cproquest_cross%3E2890389380%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3404-1c98966b4251e5fbb6aa4886c334bcee0dcd5ba1144194fd95741e45537d71d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2890389380&rft_id=info:pmid/34905279&rfr_iscdi=true